Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Jagadananda Ghosh"'
Autor:
Jitender Monga, Ritisha Ghosh, Rohith Guddeti, Dhananjay Chitale, Gazala Khan, Jagadananda Ghosh
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionPancreatic tumors and cell lines derived from them exhibit elevated expression of 5-lipoxygenase (5-Lox), whereas non-tumor glands or normal cells do not exhibit this overexpression. Arachidonic acid stimulates pancreatic cancer cell grow
Externí odkaz:
https://doaj.org/article/8718b3530ee74c79947673be7d4d9d73
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0122805 (2015)
Castration-resistant prostate cancer (CRPC) is a major clinical challenge for which no cure is currently available primarily because of the lack of proper understanding about appropriate molecular target(s). Previously we observed that inhibition of
Externí odkaz:
https://doaj.org/article/96cb1b35b00841eab950142097751488
Publikováno v:
Molecular Cancer Therapeutics. 22:381-392
FDA-approved enzalutamide is commonly prescribed to reduce the growth of advanced prostate cancer by blocking androgen receptor function. However, enzalutamide-resistant prostate cancer (ERPC) invariably develops and progresses to metastatic, lethal
Supplementary Figure 1-chemical structures of Wedelolactone and Enzalutamide.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49dd3cce49194ec28a1c86ca173ced6f
https://doi.org/10.1158/1535-7163.22506015
https://doi.org/10.1158/1535-7163.22506015
Supplementary Figures 1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f36080e898856202202ea1946d09740
https://doi.org/10.1158/1535-7163.22523851
https://doi.org/10.1158/1535-7163.22523851
Autor:
Jitender Monga, Indra Adrianto, Craig Rogers, Shirish Gadgeel, Dhananjay Chitale, Joshi J. Alumkal, Himisha Beltran, Amina Zoubeidi, Jagadananda Ghosh
Publikováno v:
The Journal of Biological Chemistry
Enzalutamide, a second-generation antiandrogen, is commonly prescribed for the therapy of advanced prostate cancer, but enzalutamide-resistant, lethal, or incurable disease invariably develops. To understand the molecular mechanism(s) behind enzaluta
Autor:
Jitender Monga, Indra Adrianto, Craig Rogers, Shirish Gadgeel, Dhananjay Chitale, Jagadananda Ghosh
Publikováno v:
Cancer Research. 82:398-398
Background: About 33,000 men will die due to prostate cancer in the US in the year 2021. Prostate cancer initially responds to androgen receptor (AR) targeted therapies (e.g., enzalutamide, darolutamide). However, therapy-resistant, aggressive, letha
Autor:
Adrianto I, Jagadananda Ghosh, Amina Zoubeidi, Himisha Beltran, Dhananjay Chitale, Monga J, Carl R. Rogers, Joshi J. Alumkal, Gadgeel S
Second-generation anti-androgen, such as enzalutamide (Xtandi), is commonly prescribed for prostate cancer therapy, but enzalutamide-resistant, lethally incurable disease invariably develops. To understand the molecular basis of enzalutamide resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ceb6422957bea8b6d24491ddc8c5d77a
https://doi.org/10.1101/2021.03.26.437250
https://doi.org/10.1101/2021.03.26.437250
Publikováno v:
Oncotarget
The cancer stem cell (CSC) concept suggests that neoplastic clones are maintained exclusively by a rare group of cells possessed with stem cell properties. CSCs are characterized by features that include self-renewal, pluripotency and tumorigenicity,
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Much of the morbidity and mortality due to prostate cancer happen because of castration-resistant prostate cancer (CRPC) which invariably develops after anti-androgenic therapy. FDA-approved enzalutamide is commonly prescribed for CRPC which works by